ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Metformin

Also written as “metformin”, “Metformin XR” and “Fenofibrate /Metformin”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus · Obesity · Fasting · Polycystic Ovary Syndrome, led by 48 companies.

Drug pageMetformin: every studyMany companies study it; this page follows only the 215 they lead. All 1,290 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Nov 9, 2005215 company-led studies, 7 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZenecaits history only290 open or runningphase 3since Nov 9, 2005Nov 9, 2005none ahead
Merckits history only190 open or runningphase 4since Oct 9, 2009Feb 15, 2005none ahead
Sanofiits history only160 open or runningphase 4since Jul 28, 2006Sep 30, 2002none ahead
GlaxoSmithKline140 open or runningphase 4since Oct 17, 2005Sep 3, 2003none ahead
Takedaits history only120 open or runningphase 4since Sep 17, 2008Jul 30, 2008none ahead
Merck KGaA, Darmstadt, Germanyits history only90 open or runningphase 4since Dec 30, 2011Dec 30, 2011none ahead
Teva Pharmaceutical Industriesits history only90 open or runningphase 1since Jan 30, 2009Jan 30, 2009none ahead
Viatrisits history only80 open or runningphase 1since Mar 30, 2008Mar 30, 2008none ahead
ADIUMits history only70 open or runningno phasesince Jun 3, 2026Jun 3, 2026none ahead
LG Chemits history only70 open or runningphase 3since Feb 6, 2013Aug 22, 2011none ahead

Also a collaborator on its studies: Parexel, PT Pharma Metric Labs, Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene, Eli Lilly and Merck, S.L., Spain.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of GlaxoSmithKline only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 3, 2003First study: phase 3 study in Diabetes Mellitus, Type 2First studyNCT00067951 · 190 enrolled · United States, Australia, Canada and more
  2. Oct 1, 2003Phase 3 study in Diabetes Mellitus, Type 2NCT00069836 · 272 enrolled · Austria, France, Germany and more
  3. Oct 17, 2005Phase 4 study in Diabetes Mellitus, Type 2NCT00241605 · 600 enrolled · Canada
  4. Jan 17, 2006Phase 3 study in Diabetes Mellitus, Type 2NCT00279045 · 4,426 enrolled · United States, Austria, Belgium and more
  5. Apr 25, 2006Phase 4 study in Diabetes Mellitus, Type 2NCT00318656 · 23 enrolled
  6. Jul 28, 2006Phase 3 study in Diabetes Mellitus, Type 2NCT00359112 · 544 enrolled · Belgium, France, Germany and more
  7. Aug 21, 2006Phase 4 study in Diabetes Mellitus, Type 2NCT00367055 · 84 enrolled
  8. Sep 12, 2006Phase 1 study in Diabetes Mellitus, Type 2NCT00376038 · 13 enrolled · Mexico
  9. Sep 21, 2006Phase 3 study in Diabetes Mellitus, Type 2NCT00379769 · 4,447 enrolled · Australia, Belgium, Bulgaria and more
  10. Jul 9, 2007Phase 3 study in Diabetes Mellitus, Type 2NCT00499707 · 453 enrolled · United States, Australia, Brazil and more
  11. May 15, 2008Phase 4 study in Diabetes Mellitus, Type 2NCT00679939 · 226 enrolled · United States, Argentina, Canada and more
  12. Sep 27, 2012Phase 2 study in Diabetic FootNCT01710527 · 32 enrolled
  13. Nov 1, 2012Phase 1 study in Diabetes Mellitus, Type 2NCT01725672 · 20 enrolled · Australia
  14. Apr 25, 2013Phase 4 study in Diabetes Mellitus, Type 2NCT01842620 · 25 enrolled

TargetBeta

“Mitochondrial complex I (NADH dehydrogenase) inhibitor; Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor”ChEMBL 37, by rule

Studies

All 14 GlaxoSmithKline leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01842620Diabetes Mellitus, Type 24CompletedMay 4, 201325
NCT01725672Diabetes Mellitus, Type 2 · Australia1TerminatedAug 21, 201320
NCT01710527Diabetic Foot2CompletedMay 18, 201232
NCT00679939Diabetes Mellitus, Type 2 · United States, Argentina, Canada and more4CompletedSep 16, 2010226
NCT00499707Diabetes Mellitus, Type 2 · United States, Australia, Brazil and more3CompletedDec 1, 2004453
NCT00379769Diabetes Mellitus, Type 2 · Australia, Belgium, Bulgaria and more3CompletedDec 20084,447
NCT00376038Diabetes Mellitus, Type 2 · Mexico1CompletedOct 200613
NCT00367055Diabetes Mellitus, Type 24CompletedOct 200884
NCT00359112Diabetes Mellitus, Type 2 · Belgium, France, Germany and more3Completed544
NCT00318656Diabetes Mellitus, Type 24CompletedOct 200723
NCT00279045Diabetes Mellitus, Type 2 · United States, Austria, Belgium and more3CompletedJun 1, 20064,426
NCT00241605Diabetes Mellitus, Type 2 · Canada4CompletedDec 1, 2005600
NCT00069836Diabetes Mellitus, Type 2 · Austria, France, Germany and more3CompletedNov 2004272
NCT00067951Diabetes Mellitus, Type 2 · United States, Australia, Canada and more3CompletedNov 1, 2004190

How it is read

Names in the registry

  • “Metformin”, 95 entries
  • “metformin”, 33 entries
  • “Metformin XR”, 11 entries
  • “Fenofibrate /Metformin”, 6 entries
  • “Sitagliptin/Metformin FDC”, 5 entries

Codes read as this program: EFB0027.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.